header logo image


Page 1,057«..1020..1,0561,0571,0581,059..1,0701,080..»

Brody: After blindness descends, finding the light – Sarasota Herald-Tribune

March 7th, 2017 6:43 pm

By Jane Brody

In letters to The Times, blind readers reacted with heartfelt reassurance and practical guidance to Edward Hoaglands essay, Feeling My Way Into Blindness, published in November.

Stanley F. Wainapel, clinical director of physical medicine and rehabilitation at Montefiore Medical Center in the Bronx, admitted that adapting to vision loss is a major challenge. But he disputed Hoaglands allusion to enforced passivity, pointing out that many advances in technology from screen-reading software for computers to portable devices that read menus or printed letters with a delay of only seconds can keep productivity, creativity and pleasure very much alive for people who can no longer see.

Rabbi Michael Levy, president of Yad HaChazakah, the Jewish Disability Empowerment Center, also acknowledged that transition to a world without sight is far from easy. But he insisted, Blindness does not cut me off from the world. He cited skillful use of a cane, travel devices that tell him where he is and what is around him and periodicals available in real time by telephone among myriad other gadgets that see for him.

Annika Ariel, a blind student double-majoring in English and political science at Amherst College, wrote that her problems are not with her blindness but rather from peoples attitudes that depict the blind as helpless and dependent. She said she travels independently, uses assistive technologies to complete her work as efficiently as others who can see, and excels academically and socially.

Equally inspiring was the response of Mark Riccobono, president of the National Federation of the Blind, who became legally blind at age 5 and lost all useful vision to glaucoma at 14.

I once let blindness make me a passenger in my own life, he wrote. That changed when I encountered a vast network of other blind people who convinced me that blindness did not define me, who taught me nonvisual ways to handle everyday and not-so-everyday tasks, and encouraged me to expect more of myself.

I am now a successful blind man married to a blind woman, living a rich, full life with her and our three children while heading a membership organization that helps tens of thousands of blind people. He met his wife, who was born blind, when they were both students at the University of Wisconsin.

Riccobono, 40, said that he grew up trying to hide his blindness until he met people at the federation who taught him that it was respectable to be blind and that he could do things as effectively as sighted people do.

Ive taught many blind people to use a chain saw, he told me, noting that many activities that we assume require vision really dont.

A screen-reading computer program called Jaws enables Riccobono to read whats on the screen, type and send email using synthesized speech. With the KNFB Reader app on his smartphone, three clicks on the home button turns it into a reading machine that takes pictures of text a menu, label, whatever and reads it out to you, he said.

He credited his federation with having built the best news information source out there the NFB Newsline, with access to hundreds of publications, breaking news, weather that delivers information orally by telephone, on a mobile phone, on a computer via a screen reader or in Braille.

He navigates using a long white cane, which he described as one of the most elegant pieces of technology for blind people. I find things with my cane and plunk the image into a mental map of my environment. He also uses the same GPS system available to sighted people.

Riccobono emphasized the importance of being proactive before a progressive disorder destroys vision entirely. Two of his three young children have the same condition that rendered him blind, and while they can still see, they are learning to read both print and Braille.

He advised me to tell my three friends who have varying stages of age-related macular degeneration to start now to learn to use the tools they will need when they can no longer see clearly. It will make their adjustment that much easier, he said.

The American Council for the Blind has an online list of all manner of products that can smooth the way for people with limited or no vision, including information on where to buy them. Products range from voice-activated television remotes and talking calculators to sewing and kitchen aids. There are also products for people with both vision and hearing loss.

Equally important is for sighted individuals to know how to interact effectively with people who are blind or visually impaired. First and foremost, be sure to identify yourself by name (and association, if your name may not immediately ring a bell). Dont assume the person can recognize you by your voice.

Dont channel your remarks through a third person, and speak naturally. Dont restrict your use of words like see or look when they are a logical component of a conversation. And dont raise your voice, unless the person who cant see also cant hear well.

Dont assume. Always ask first if the person needs help, whether that involves crossing a street, finding a building or carrying a package. When providing directions, be specific, using words like on the left or on the next corner.

Continue reading here:
Brody: After blindness descends, finding the light - Sarasota Herald-Tribune

Read More...

Organic semiconductor could reverse degenerative blindness – physicsworld.com

March 7th, 2017 6:43 pm

An organic retinal implant designed in Italy can stimulate retinal neurons and send signals to the brain, restoring near-normal vision indefinitely to rats with degenerative blindness without causing apparent damage to the rats' eyes. That's the claim of the researchers who developed it, who believe it could potentially lead to treatments for a major cause of blindness in humans. Other researchers, however, are more cautious.

Retinitis pigmentosa describes multiple genetic disorders that cause the photoreceptors on the retina to die. These lead to blindness, even though the other neurons concerned with signal processing and the optic nerve remain functional. There is currently no effective clinical treatment for the condition, but several groups are developing various proposals to effectively replace these lost photoreceptors by stimulating the retinal neurons artificially. While this could one day restore a patient's vision, these approaches face severe difficulties. For example, most of the implants require a power supply, and wiring into the eyeball is extremely tricky. One solution is a photovoltaic cell that generates a voltage using only the incoming light, but this faces two principal problems. First, previous researchers have found the intensity of ambient light insufficient to stimulate the neurons. Secondly, silicon is much stiffer than nervous tissue: "In the long term, [silicon] can induce a reaction by the tissue," says neuroscientist Fabio Benfenati of the Center for Synaptic Neuroscience and Technology in Genoa, leading to encapsulation, [scarring] and things like that."

In the new research, materials scientist Guglielmo Lanzani of the Center for Nano Science and Technology in Milan and colleagues designed a more flexible, organic retinal implant based on a polymer solar cell. They deposited a thin layer of conductive polymer onto a silk-based substrate and covered it with a semiconducting polymer. When the semiconductor absorbs a photon, it creates an electronhole pair called an exciton. The positive holes are drawn into the conducting polymer, whereas the electrons remain in the semiconductor, causing a negative charge.

Surgeons led by ophthalmologist Grazia Pertile of Sacro Cuore Hospital near Verona implanted the devices underneath the retinas of Royal College of Surgeons (RCS) rats a strain of rats that reliably develop retinitis pigmentosa owing to a genetic mutation also found in some human cases of the disease. They placed the implants such that the semiconducting polymer was in contact with the retinal neurons, so absorption of light would apply a negative voltage to the cells. After 30days, when the swelling from the surgery had completely subsided, Benfenati's group compared the rats' vision with both untreated RCS rats and healthy rats.

They first tested the pupil's contraction in response to light, finding that although it was significantly impaired in untreated RCS rats, it was near normal in rats with the implant. In further tests using an electrode in the primary visual cortex, the researchers showed that implanted rats' light sensitivity and visual acuity was substantially better than that of untreated RCS rats, and positron emission tomography showed that the metabolism of their primary visual cortices was higher. Furthermore, the rats which naturally prefer dark environments avoided light more effectively.

The researchers tested the rats again later, both after 180days and after 300days: they found that, although the quality of the implanted rats' vision declined, it stayed just as good relative to the other rats. "There is a generalized decrease in [the rats'] sight with age," explains Benfenati. The recovery of the rats' vision appears greater than can be explained by simple photovoltaics, so the researchers suspect other effects are involved, although precisely what these are remains unclear.

After dissecting the rats, the researchers tested prostheses removed from their eyes and showed that they worked similarly to prostheses stored in sterile conditions. The researchers are now testing an adapted implant in pig's eyes: "We believe, based on these data, we could probably attempt the first [human] implant...within the next two years," says Benfenati.

"The article is indeed interesting," says ophthalmologist Mark Humayun of the University of Southern California in Los Angeles. He is impressed by the simplicity of using light to stimulate the implant, although he cautions: "The RCS rat retina is known to be much easier to stimulate. When it comes to a patient with longstanding retinal degeneration, we have found that ambient light intensity is insufficient and it requires intensified light often multiple Suns."

Daniel Palanker of Stanford University, is more sceptical, noting that, in their laboratory tests of the implant, the researchers use light six million times more intense than some light levels to which the rats responded. "This indicates that the visual response has nothing to do with the photovoltaic response of the polymer," he concludes. Instead, he suggests it is probably an unidentified factor (called a trophic factor) that extends the life of degenerating neurons. This is a well-documented effect of a retinal implant (even a non-functional one), and the researchers attempt to rule out this explanation by showing that a silk implant without the photovoltaic coating does not work. Palanker, however, is unconvinced: "Their control implant is much thinner (0.8m) than the real one (30m), and I suspect it could not be implanted as a flat layer," he says, "Therefore it cannot serve as a real control.

The research is described in Nature Materials.

Visit link:
Organic semiconductor could reverse degenerative blindness - physicsworld.com

Read More...

iShares Nasdaq Biotechnology Index (ETF) (IBB) Is at a Crossroads – Investorplace.com

March 7th, 2017 6:42 pm

By Serge Berger, Head Trader & Strategist, The Steady Trader|Mar 7, 2017, 8:02 am EST Popular Posts: Recent Posts:

Biotechnology stocks as represented by theiShares Nasdaq Biotechnology Index (ETF)(NASDAQ:IBB) have rallied 13% year-to-date. Thats notable considering that over the past 12 months, the IBB ETF has only rallied by about 14%.

Many traders in recent days have pointed to the continued strength in biotech stocks as a sign that the broader market is not yet ready to roll over. But it is notable that the IBB, as a result of the recent rally, has now reached an important technical level on the charts that may offer better technical resistance.

A simple yet effective trick that I repeatedly use to gauge the internal strength of the broader stock market is by checking the pulse of the so calledrisk-on groups. While these groups change over the years, they often include technology and financial stocks. In recent years, biotech, tech as a whole and small-cap stocks, among others, have led the risk-on pack.

Over the past few weeks, biotech stocks and the IBB ETF have showed both absolute and relative strength versus the broader stock market. Through this lens, one could argue that it is premature to get too defensive on the stock market in the near-term and possibly the intermediate-term until biotech stocks begin to back off some.

When I last discussed the state of biotech stocks on Feb. 1,I offered that the IBBs bullish reversal from Jan. 31 could be the beginning of a next swing higher with price targets in the$285-$290 area. Two weeks later, the upper end of this price target had been reached, and last week the IBB ETF further extended this rally into the $300 level.

Now, lets look at the charts.

On the multiyear weekly chart, we see that this recent rally has brought the IBB back to the very upper end of a sideways channel, which now also lines up with the 100-week simple moving average (blue).

Click to Enlarge

This confluence of technical resistance around the $300 area could provide a more meaningful challenge to be overcome.

Next Page

Article printed from InvestorPlace Media, http://investorplace.com/2017/03/ishares-nasdaq-biotechnology-index-etf-ibb-is-at-a-crossroads/.

2017 InvestorPlace Media, LLC

Excerpt from:
iShares Nasdaq Biotechnology Index (ETF) (IBB) Is at a Crossroads - Investorplace.com

Read More...

Biotechnology group names Thune its legislator of the year – Watertown Public Opinion

March 7th, 2017 6:42 pm

SIOUX FALLS Sen. John Thune (RS.D.) has been named Legislator of the Year from the international Biotechnology Innovation Organizations Industrial & Environmental Health Section.

The award recognizes Senator Thunes support of the biotechnology industry and steadfast commitment to growing South Dakotas and the nations bio-based economy.

Thunes award was presented by Doug Berven, a member of BIOs governing board and vice president of corporate affairs at Sioux Falls-based POET, and Brent Erickson, executive vice president of BIOs Industrial & Environmental Section.

Sen. John Thune has been a strong and constant champion of policies that support industrial biotechnology companies in creating jobs, revitalizing manufacturing, improving U.S. energy security and building a bio-based economy, Erickson said.

Senator Thune was first elected to the Senate in 2004, when the first Renewable Fuel Standard was under development. He helped expand the program in 2007 and has been a determined advocate in encouraging the Environmental Protection Agency to get the program on track for future growth.

Thune also was recognized helping renew tax credits for second-generation biofuels and for co-sponsoring legislation to ensure mandatory funding for energy programs in the Agriculture Act of 2014.

Through his efforts, Congress has incorporated innovative programs in the Farm bill to spur the development of biomass, purpose grown energy crops, bio-based products and renewable chemicals, Erickson said.

Thune is a strong and consistent advocate for biotechnology in his home state as well, said Joni Johnson, executive director of South Dakota Biotech, the state affiliate for BIO.

See the rest here:
Biotechnology group names Thune its legislator of the year - Watertown Public Opinion

Read More...

Study Free Profits From iShares Nasdaq Biotechnology Index (ETF) (IBB) Stock – Investorplace.com

March 7th, 2017 6:42 pm

The biotech industry had a rough 12 months. First the beatings came from presidential hopeful Hillary Clinton as she vowed to crush their pricing models. Now President Donald Trump is following up with similar promises.

For a long while, tickers like the iShares Nasdaq Biotechnology Index (ETF) (NASDAQ:IBB) were toxic to investors. The thesis was that healthcare and biotech companies were untouchable with the political cloud looming above them.

Recently, and in spite of the fact that that nothing has changed from the political standpoint, the worrisome headlines became stale and lost their zing. Thats what usually happens. Traders initially over-react to the headline and then after a while, return to trading the fundamentals.

The companies in the IBB have legitimate, viable businesses. This is a classic case of a bad apples who spoil the bunch.

Technically the IBB stock price is in a breakout that I rode higher on Feb. 11 with debit call spreads.

The important price action came when the IBB reclaimed the $280 per share pivotal zone. From here at the $300 per share level, it can once again provide a base from which to mount another leg higher. This area is an important long term pivot level so has the potential to be a solid base once it is cleared.

Click to Enlarge The ongoing IBB measured move has more upside potential, but there is also resistance looming above. Whats important to me as a premium seller is to find areas where price is not going so I can safely sell risk for income.

Now that Wall Street is repricing the IBB where it should be in spite of the headlines, I want to sell downside risk.

Finding the right level can be tricky. Biotech companies are susceptible to big moves on surprise headlines. Even though the IBB risk is spread among its components, they tend to trade in unison. So if one component of the IBB moves on a headline, the rest would follow in sympathy. This makes trading IBB via sold premium as risky as a single momentum headline stock.

The Bullish Trade: Sell the IBB Jan 2018 $255/$250 credit put spread. I collected $1 per contract to open which would be a 25% yield on risk if I win. The 15% price buffer gives this trade an 85% theoretical chance of success.

Usually I like to hedge my bet. In this case I will sell opposite risk so to balance the trade. There is no rush to do so in this uber-bullish markets. So I could delay entry until I see an abatement in the exuberance over biotech stocks.

The Hedge (optional): Sell the IBB Jan 2018 $355/$360 credit call spread. I collect an additional $1 per contract to open.

If I take both sides then I would be in a sold iron condor where I need IBB to stay between $255 and $355 per share. If IBB stays in the range, this trade would yield over 60% on money risked.

I am not required to hold my options trades open through expiration. I can close either at any time for partial gains or losses.

Nicolas Chahine is the managing director of SellSpreads.com. As of this writing, he did not hold a position in any of the aforementioned securities. You can follow him on Twitter at @racernicand stocktwits at@racernic.

Original post:
Study Free Profits From iShares Nasdaq Biotechnology Index (ETF) (IBB) Stock - Investorplace.com

Read More...

RBC Capital Markets Cuts Puma Biotechnology Inc (PBYI) Price Target to $17.00 – The Cerbat Gem

March 7th, 2017 6:42 pm

The Cerbat Gem
RBC Capital Markets Cuts Puma Biotechnology Inc (PBYI) Price Target to $17.00
The Cerbat Gem
Puma Biotechnology Inc logo Puma Biotechnology Inc (NYSE:PBYI) had its target price reduced by RBC Capital Markets from $48.00 to $17.00 in a research note issued to investors on Thursday morning. They currently have a sector perform rating on the ...
Puma Biotechnology Shares Plunge On Plans To Modify Neratinib European MAA, Competitor Roche's Perjeta WinBenzinga
The Puma Biotechnology Inc (PBYI) Price Target Cut to $17.00 by Analysts at RBC Capital MarketsDailyQuint
Puma Biotechnology Inc Realized Volatility Hits A Notable HighCML News
Smarter Analyst -Yahoo Finance -Sports Perspectives
all 96 news articles »

Read more from the original source:
RBC Capital Markets Cuts Puma Biotechnology Inc (PBYI) Price Target to $17.00 - The Cerbat Gem

Read More...

‘This is not your mother’s arthritis’: Most cases found in younger Americans – CNN

March 7th, 2017 6:41 pm

That number is "alarmingly high," according to a report released Tuesday.

About 54.4 million American adults have had a doctor diagnose them with painful joint inflammation and stiffness, according to the new Centers for Disease Control and Prevention Vital Signs Report. That breaks down to about one in four adults in the nation.

The number is probably an under-count since it does not include those who have had to go into nursing home care because of it. It also does not include people who may be suffering but haven't gone to the doctor.

"This is not your mother's arthritis," Acting CDC Director Anne Schuchat said. "Contrary to popular opinion, it is not an old person's disease."

Aging baby boomers aren't the only ones who have it. The majority of current cases of arthritis -- 32.2 million -- are in people under age 65. Women have it more than men, and the number is particularly acute for diabetics, heart patients and those struggling with obesity. About 49.3% of people with heart disease have arthritis, 47.1% of diabetics and 30.6% of people who are obese.

The new numbers come from self-reported data collected between 2013 and 2015.

The research also found that 23.7 million Americans with arthritis have had to limit their activities because of the pain. Some say they can't bend or stoop. Others report having difficulty kneeling or struggle with holding a cup; others find it tough to walk even three blocks.

Many people with arthritis take some kind of pain medication, including opioids, but there are safer and cheaper options.

"We do have to be careful about these exercise recommendations, though," said Guy Eakin, senior vice president of scientific strategy with the Arthritis Foundation. "We have more than 100 types of arthritis." That means some people can't exercise their way out of the pain, but many can and shouldn't be afraid to bike, walk or swim.

Eakin said more research into how to fight arthritis is needed. He, McDaniel and 400 other advocates went on Capitol Hill on Tuesday to talk to Congress about how to better invest in the disease.

Today, the condition costs the country $81 billion, and that number will probably go up. By 2040, scientists project, arthritis will affect 78.4 million people.

"The cost of care is dramatically outpacing what the country is putting into research," Eakin said. "Arthritis can rob people of their lives, and as a leading cause of disability, it is why people retire and go into assisted living, and it's a dramatic cost to our national economy. We can't fix health care if we can't fix arthritis."

Follow this link:
'This is not your mother's arthritis': Most cases found in younger Americans - CNN

Read More...

Natrual remedies available for nagging arthritis pain – Beatrice Daily Sun

March 7th, 2017 6:41 pm

Dear Doctor: Are there natural remedies for arthritis? Exercises that could help? My pain is in the upper arms and shoulders.

Dear Reader: Osteoarthritis, the kind that you're describing, is caused by degeneration of the cartilage within a joint. Without the cartilage, one bone rubs upon the other, leading to pain and degeneration of the bone.

Doctors typically recommend nonsteroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, naproxen and aspirin; acetaminophen; and, more rarely, opiates. But NSAIDs can increase the risk of stomach ulcers and kidney problems when used chronically; acetaminophen at high doses can cause liver problems when used chronically; and opiate medications can lead to addiction. So I can understand your desire to look for an alternative for the pain.

The supplements chondroitin sulfate and glucosamine have been used for osteoarthritis for years. Chondroitin is one of the building blocks of cartilage in our body, so many people naturally believe that taking chondroitin can decrease the pain of arthritis.

A 2015 review of 43 randomized trials compared the use of chondroitin alone or in combination with glucosamine against the use of a placebo. Most of these studies looked at treatment for arthritis of the knees, with some looking at arthritis of the hips and hands. The studies measured pain on a 100-point scale. The use of chondroitin was found to be beneficial, whether with or without glucosamine, showing a small 8-point difference in pain compared with placebo. It didn't ease the stiffness and lack of mobility associated with arthritis, however.

In another study, a randomized trial of 606 patients with pain from osteoarthritis of the knee compared the use of glucosamine with chondroitin against the anti-inflammatory drug celecoxib (Celebrex). After six months, both groups found a greater than 50 percent reduction in both pain and joint swelling. What was interesting about the study was that it took a while for the glucosamine/chondroitin to work. At one to four months, Celebrex was much better at improving pain, but at six months it was no different than the glucosamine/chondroitin combination. So with the use of glucosamine and chondroitin, it is important to be patient.

The supplements MSM (methylsulfonylmethane) and DMSO (dimethyl sulfoxide) are anti-inflammatory agents that have been studied in arthritis of the knees without evidence of benefit, but it's possible they could decrease pain in the joints of the hands. Arnica montana is a plant-based therapy that has some potential in topical use for pain relief, with one study finding a slight benefit for arthritis of the hands. Topical use of capsaicin cream, made from chili peppers, has shown potential as well, specifically for arthritis of the knee. Other natural remedies and supplements, such as fish oil, are touted for arthritis, but their use has not been well studied.

As for exercises, I would recommend physical therapy to increase your range of motion for your shoulder and to help increase your muscular strength. Yoga, Pilates and tai chi can also be beneficial, potentially increasing your range of motion without undue stress on your already aching joints. Over time, you may well see a difference in your ability to function with less pain.

Robert Ashley, M.D., is an internist and assistant professor of medicine at the University of California, Los Angeles.

Excerpt from:
Natrual remedies available for nagging arthritis pain - Beatrice Daily Sun

Read More...

Arthritis patience wearing thin across the province – TheChronicleHerald.ca

March 7th, 2017 6:41 pm

Many Nova Scotians suffer with the pain of osteoarthritis. In fact, Nova Scotia is the province with the highest rate of osteoarthritis in Canada. This high rate of osteoarthritis may be due, at least in part, to the high number of seniors within Nova Scotia. We have the highest percentage of seniors in Canada, with more than 18 per cent of the population being 65 years of age or older.

In cases of advanced osteoarthritis of the hip or knee, a joint replacement procedure is an excellent treatment which provides pain relief and significant improvements in mobility. However, Nova Scotians may have to wait extended periods of time in order to receive a joint replacement.

Statistics were released recently by Nova Scotias auditor general on knee and hip replacement wait times here in Nova Scotia. The wait times are worrisome and falling far behind the national average. While the national benchmark for these joint replacement procedures is six months, Nova Scotians suffering with advanced arthritis are waiting over two years on average.

Many factors contribute to these lengthy wait times, including the number of people needing these surgeries, healthcare infrastructure and a shortage of doctors, nurses and other healthcare professionals.

Many people suffering with arthritis find themselves waiting for a joint replacement for extended periods of time (years) with pain which limits their lives. Unfortunately these arthritis sufferers may not be able to perform some activities of daily life including gardening, lifting heavy objects, doing yard work and walking short distances in some cases. Thankfully there are things which can be done in the meantime in order to limit the pain and disability associated with osteoarthritis of the hip and knee.

Exercise: Although exercise can be uncomfortable at times for some arthritis sufferers the discomfort typically eases after the first few minutes of exercise. The key is doing light to moderate levels of exercise on a regular basis and aiming to meet Canadas physical activity guidelines of at least 150 minutes of aerobic exercise per week and two sessions of strengthening exercise per week. These goals could be achieved by walking briskly for 30 minutes five times per week and having two strength training sessions at a gym per week.

Weight management: Keeping a healthy bodyweight is important for the management of arthritis associated pain. If a person with osteoarthritis is overweight losing weight will help to alleviate their pain and improve their mobility.

Platelet-rich plasma (PRP): A PRP injection is a treatment for osteoarthritis which research has shown can provide lasting relief for the pain associated with osteoarthritis. This treatment uses a small amount of a persons own blood plasma which is rich in platelets. Platelet rich plasma works by introducing platelets (which are rich in growth factors) directly to the site of damage. This high concentration of growth factors stimulates healing within the arthritic joint. PRP is a safe treatment as it uses simply a component of your own blood.

Read more:
Arthritis patience wearing thin across the province - TheChronicleHerald.ca

Read More...

Hospital group invests $20M in stem cell therapy biotech – FierceBiotech

March 7th, 2017 6:41 pm

Hospital group Sanford Health has invested $20 million in InGeneron to support clinical trials of a stem cell regenerative medicine. The Series D gives Sanford a financial stake in an adipose-derived stem cell therapy it is testing in a clinical trial at its network of healthcare facilities.

InGeneron began working with Sanford on an 18-person trial of its stem cell injection in patients with partial thickness rotator cuff tears around the turn of the year. And the network of 45 hospitals and close to 300 clinics has now tightened its ties to InGeneron by investing $20 million in the Houston, TX-based regenerative medicine company. InGeneron sees benefits in strengthening its relationship with Sanford.

This significant investment demonstrates Sanfords commitment to be an active participant in InGeneron as well as being our clinical trial site of choice. Our joint efforts will enable the company to make regenerative cell therapies available to clinical practice and to establish a leading position in the application of adipose-derived regenerative cells, InGeneron President Ron Stubbers said in a statement.

Sanford runs the two trial sites that are enrolling patients in the aforementioned 18-person trial. Both sites specialize in orthopedics and sports medicine. Rotator cuff injuries are associated with overhead sports, such as baseball and tennis. The healthcare system is presenting its close involvement with InGeneron as a positive for the patients it serves because it facilitates early access to an experimental therapy.

The treatment entails processing adipose tissue harvested during liposuction to create a mixture containing stem cells and nutrients. This mixture is injected into the site of the injury. In the trial, one-third of participants will form a control arm and receive a cortisone injection instead of stem cells.

The exec team tells FierceBiotech that the first patients were enrolled in the feasibility trial for rotator cuff tendinopathy in January, with U.S. regulatory market approval "anticipated in 2020."

InGeneron last raised money last year through a $4.5 million seed round. That financing, which came 10 years after InGeneron was founded, followed studies of the companys cell therapies in knee surgeries. InGeneron also makes biomedical equipment for collecting and processing adipose tissue.

The biotech has and its subsidiaries on both sides of the Atlantic has a team of 30 people, and has raised $38 million to date.

Read this article:
Hospital group invests $20M in stem cell therapy biotech - FierceBiotech

Read More...

Stem Cell Therapy receives FDA Boost to enter the US Market – Labiotech.eu (blog)

March 7th, 2017 6:41 pm

TiGenix has receivedpositive feedback from the FDA on an improved global phase III trial protocol for its lead candidateCx601 for Crohns disease. This is expected tospeed up US approval.

TiGenix is a Belgian companydevelopingstem cell therapies. The biotech is currently pushing its lead candidateCx601to the market for the treatment ofcomplex perianal fistulas in Crohns disease patients. Cx601 recently revealedpositive resultsin a European phase III study.

Following these results, the company submitted a number of technical adjustments for itspivotal phase III study for Biologics License Application (BLA) in the US, which were now approved by the FDA and are expected to acceleratethe process to US marketing authorization.

TiGenix is wellknown for its productChondroCellect, which was the first cell therapyto reach approval on the European market for the repair of knee cartilage.After the companyrecently withdrew its market authorization for this product, due to a lack of reimbursement, the biotech is focusing on its new leadCx601.

Thisproduct, currently awaiting EMA approval, consists ofallogeneic expanded adipose-derived stem cells (eASC), which are indicated for the treatment ofperianal fistulas in Crohns disease. The therapeuticeffects of eASCs are based on immunomodulatory abilities of these stem cells, which canrestore immune balance by suppressing a variety of immune cell subsets and inducing the generation of regulatory T cells.

Areas of the colon commonly affected duringCrohns disease

The current approval from the FDA will allow TiGenix to file the BLAbased on the efficacy and safety follow-up of patients at week 24, instead of week 52.The FDA has also agreed to accept fewer patients than originally planned in the study and endorsed a broader target population that will ultimately facilitate the recruitment process.

We believe that this revised protocol will allow us to file for approval one year earlier than we had originally plannedconcludedMaria Pascual, VP Regulatory Affairs & Corporate Quality of TiGenix

The current amendments will allow TiGenix to push its therapyto the US market even faster, which might pivotal for the company in light of its financial situation. After its shares had reached a low of22 cents back in 2013, the share price is currently still under 1. Withits low 34M IPO on Nasdaq in the end of last year, its market cap is stillonly at 191M. A low sum for a late stage clinical company.

As the EMAapproval forCx601 is expected soon, which will then be commercialized by Takeda, the company may actually be underestimated. The biotech recently started a new Phase Ib/IIa trial to testCx611 as a treatment for sepsis in patients with pneumonia.

Asecond platform consisting of transplanted allogeneic cardiac stem cells (AlloCSC)is currently in Phase II for acute myocardial infarction. It seems like TiGenix is definitely clinging toits position as one of the pioneers in stem cell-based therapies.

Images via shutterstock.com / CI Photos and CC 3.0 /RicHard-59

More here:
Stem Cell Therapy receives FDA Boost to enter the US Market - Labiotech.eu (blog)

Read More...

Stem Cell Therapy Market by Type, Therapeutic Application, Cell Source – Global Forecasts to 2021 – Yahoo Finance

March 7th, 2017 6:41 pm

NEW YORK, March 7, 2017 /PRNewswire/ -- l stem cell therapy market is estimated to grow at a CAGR of 11.0% during 2016 to 2021 to reach USD 145.8 million by 2021. Growth in the global stem cell therapy market is driven by factors such as the growing awareness of the therapeutic potency of stem cells in effective disease management, development of advanced genome-based cell analysis techniques, increasing public-private investments for development of stem cell therapies, identification of new stem cell lines, and developments in infrastructure related to stem cell banking and processing. In addition, countries such as Japan, South Korea, and China are offering new growth opportunities for players operating in this market. The North American region is expected to command the largest share in the stem cell therapy market in 2016.

Read the full report: http://www.reportlinker.com/p04759526-summary/view-report.html

Based on the type of therapy, the allogeneic stem cell therapy segment is estimated to command the larger share of the global stem cell therapy market in 2016. This growth can be attributed to the growing availability of allogeneic stem cell therapy products, wider therapeutic applications of allogeneic stem cells, easier production scale-up due to easy availability of sources of stem cells, and growing number of clinical trials of allogeneic stem cell therapies as compared to autologous stem cell therapies.

The stem cell therapy market is niche industry with a growing number of global and local companies involved in the development and commercialization of stem cell therapy products. Osiris Therapeutics, Inc. (U.S.), MEDIPOST Co., Ltd. (South Korea), Anterogen Co., Ltd. (South Korea), and Pharmicell Co., Ltd. (South Korea) were the leading players in the global stem cell therapy market in 2015. New product launches and approvals; expansions; and partnerships and agreements are the major strategies adopted by most of the market players to achieve growth in the stem cell therapy market during 20132016.

Research Coverage This report studies stem cell therapy market based on type of therapy (allogeneic and autologous). These stem cell therapies are used for the treatment of various diseases (including musculoskeletal disorders, wound healing, CVDs, and GI diseases, among others). The report also studies, the factors (such as drivers, restraints, opportunities, and challenges) which affect the market growth in a positive and negative manner. It analyzes opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report forecasts the revenue of the market segments with respect to four main regions, namely, North America, Europe, Asia-Pacific, and the Rest of the World. The stem cell therapy market report strategically profiles the key players who are involved in the manufacturing and commercialization of stem cell therapy products and comprehensively analyze their market ranking and core competencies. The report tracks and analyzes competitive developments such as new product launches and enhancements; expansions; and partnerships and agreements in the stem cell therapy market.

Reasons to Buy the Report:

From an insight perspective, this research report focuses on various levels of analysismarket share analysis of the top players and company profiles, which together comprise and discuss basic views on the competitive landscape; emerging and high-growth segments of the stem cell therapy market; and high-growth regions and their respective drivers, restraints, challenges, and opportunities.

The report will enrich both established firms as well as new entrants/smaller firms to gauge the pulse of the market, which in turn will help firms in garnering a greater market share. Firms purchasing the report could use any one or a combination of the below-mentioned five strategies (market penetration, product development/innovation, market development, market diversification, and competitive assessment) for strengthening their market shares.

The report provides insights on the following pointers:

- Market Penetration: Comprehensive information on products offered by the top 10 players in the stem cell therapy market. The report analyzes the stem cell therapy market by type, therapeutic application, cell source, and region

- Product Development/Innovation: Detailed insights on research and development activities, developmental product pipeline, and new product launches in the stem cell therapy market

- Market Development: Comprehensive information about the lucrative emerging markets. The report analyzes the markets for various stem cell therapy products across four geographies (North America, Europe, Asia-Pacific, and the Rest of the World)

- Competitive Assessment: Assessment of market shares, strategies, products, distribution networks, and manufacturing capabilities of the leading players in the stem cell therapy market

Read the full report: http://www.reportlinker.com/p04759526-summary/view-report.html

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

http://www.reportlinker.com

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

Read More

Read the rest here:
Stem Cell Therapy Market by Type, Therapeutic Application, Cell Source - Global Forecasts to 2021 - Yahoo Finance

Read More...

Stem Cell Therapy An Option For ENC Patients – Public Radio East

March 7th, 2017 6:41 pm

Stem cell therapy is a quickly advancing treatment being used across the country. Now, its becoming more prevalent in eastern North Carolina to those living with chronic pain an alternative to surgery. The minimally invasive procedure is showing results in alleviating back, knee, hip and shoulder pain. Though stem cell therapy is classified by the Food and Drug Administration as experimental, patients say theyre finding relief. Meet New Bern resident and a local endodontist Dr. Donnie Luper. He was skeptical of the procedure at first.

How did you know what those stem cells were going to differentiate into? I mean was I going to grow a foot out of my shoulder or something like that?

Luper tore his rotator cuff 25 years ago during a tubing incident on the Trent River. A subsequent fall during a golf trip in 2015 sent him to a specialist.

I went to see a shoulder surgeon in Richmond. He told me that he didnt think it was a complete tear of my rotator cuff, that I could probably have a minor surgical procedure done and I asked him about stem cell.

After talking with a friend who opted for stem cell treatment for her knee pain, Luper decided to find out more.

My option was if I would have had that shoulder surgery and they had do that bicep tendon repair, I mean I would have been in a sling for six weeks and probably not working for three months.

According to the Food and Drug Administration, stem cells sometimes called the bodys master cells - have the ability to divide and develop into many different cell types. Each new cell has the potential to remain a stem cell or become another type of cell, such as a nerve cell, a skin cell, or a red blood cell. They may also help repair the body by dividing to replenish cells that are damaged by disease, injury or normal wear. Parkinsons disease, spinal cord injuries, damaged organs and cancer could all be possibly treated with the use of stem cells, but more research is needed. Dr. Angelo Tellis is the owner/physician of Aegean Medical, which provides stem cell therapy to patients in Cary, Jacksonville, Morehead City and New Bern.

The adult stem cells we call multipotent stem cells so they can only differentiate into very specific or certain kinds of tissue. Whereas the embryonic stem cells we call pluripotent and can become a variety, almost any tissue. But I only deal with adult stem cells, theyre found to be more useful in clinical applications.

Dr. Tellis says adult stem cells are more responsive to growing tissue in very specific locations. When patients go into Dr. Tellis office for the two hour procedure, he starts by numbing an area of the abdomen and performing liposuction to collect one or two syringes of body fat.

Stem cells can be found in a lot of different tissues throughout the body, but theyre actually in one of the highest concentrations in your own body fat.

The stem cell sample is combined with platelet rich plasma or PRP collected through a blood draw.

That has a lot of the chemical signals and messengers that activate stem cells. So Ill typically combine that with some of the stem cells collected from the body fat and then go under x-ray guidance and put it exactly in the targeted location where we want to create that healing process.

Soreness and stiffness can be expected immediately following the procedure and for about a week after. Dr. Tellis says the results tend to improve with time, taking about three to six months for full recovery. This was Lupers experience in 2016.

Really didnt have to take any pain medications. The joint was really sore over the weekend just because of the injection of the fluid there and after that, I had a small amount of discomfort, but nothing I really had to take medication for.

After three months, Luper says he felt 90 percent better. But he decided to get a second opinion from a shoulder surgeon.

And he told me he thought the stem cells had done a lot but that I still had one little bone spur that was rubbing against the muscle and constantly tearing the little bit of the muscle.

After surgery, Luper says his left shoulder started feeling significantly better in about a month. He was also able to return to one of his favorite pastimes golf. While surgery helped eliminate all of his pain, Luper believes stem cells helped regenerate tissue that was damaged years ago.

He said my rotator cuff muscle didnt even look like it had been torn. I actually tore that, Im sixty now, and I actually tore that when I was 34, 35 tubing on the river and I had to do physical therapy for about three months, but he said he saw absolutely no evidence that Id ever had a rotator cuff tear.

Even though some have found relief and possibly a cure through stem cell therapy, the Food and Drug Administration has not approved any stem cell-based products for use, other than HEMACORD (HE-muh-cord). According to their website, the use of stem cells raises safety concerns such as excessive cell growth, the development of tumors as well as cells migrating from the site of administration and differentiating into inappropriate cell types. And then, theres the cost of the procedure, which is not covered by insurance. The price for the treatment ranges from $2,500 to $5,000. But for those who want to avoid major surgery and the downtime associated with recovery, the risk and cost may be worth it.

If Id have surgery, my deductible would have been that because I have an out-of-pocket max. And I would want to do anything to avoid surgery, especially something that would keep me out of work for three months.

The FDA recommends that consumers interested in stem cell therapy should start a conversation with their doctor about the potential risk to benefit ratio. In addition to Aegean Medical, Advanced Health and Physical Medicine in Greenville and Regenerative Medicine Clinic of Wilmington also provide stem cell therapy in eastern North Carolina.

Read more:
Stem Cell Therapy An Option For ENC Patients - Public Radio East

Read More...

Is Alzheimer’s treatment of injecting stem cells into the brain a breakthrough or quackery? – The Mercury News

March 7th, 2017 6:41 pm

More than eight years after he realized something was wrong, after, as he described it, My brain went

Whats the word? Foggy, Jack Sage finally said after several seconds of silently coaxing his synapses to fire.

More than eight years after his brain went foggy, four years after he was diagnosed with Alzheimers disease and two years since he began an innovative and extremely invasive therapy, Sage said he is being flooded by memories that seem new, or, at the very least, feel easier to retrieve. His daughter, Kate, thought Sage had suddenly begun to open up about his past because he knew his time was growing short.

He should not know who I am at this point, Kate said.

His doctor, Christopher Duma, hopes Jack Sage goes down in history as the one-man turning point in the treatment of Alzheimers disease, while others are skeptical about what Duma has done to Sages brain. Everyone agrees that Alzheimers disease is an exploding problem.

The California Alzheimers Disease Data Report from 2009 projected a 67 percent increase between 2015 and 2030 in residents in Los Angeles, Orange, Riverside and San Bernardino counties living with Alzheimers disease up to 498,137. The same report references a study, between 2000 and 2004, in which 58 percent of the deaths among people 65 and older in California were attributed to Alzheimers disease. New numbers will be released Tuesday.

The Alzheimers Association reported that 610,000 Californians 65 or older had the disease in 2016, and it estimated increases to 690,000 by 2020 and 840,000 by 2025.

On a cool recent night, Sage, a handsome, fit, 82-year-old, sat next to his wife Gloria talking about his children (It is significant that Sage remembers their names James, 46, Kate, 50, and Kelly, 56), recalling when he and Gloria moved into the Newport Beach house with a view of the Pacific Ocean (1990), laughing about their first date at the Bel-Air Country Club (1979), recounting his years as a labor negotiator and executive for Del Monte, Allied Chemical and Continental Airlines (1970s and 60s) and going all the way back to the jack hammering he did in the nickel mines (mid-1950s) in Northern Ontario, Canada.

At this point in his illness, his doctor said he should be having more trouble remembering the perilous tunnels of the Sudbury nickel mine.

You drill into the granite, Sage said. You put dynamite in the rock. You dynamite it. Then you shovel out whats left.

And mining, you might say, is what is happening in Jack Sages brain.

Sages series of recollections, including his exploits on the golf course in Indian Wells where he has a second home and plays several days a week flashbacks representing the three main components of long-term memory: semantic (recalling the meaning of words), episodic (recalling autobiographic milestones) and procedural (recalling how to accomplish tasks) prompted a grin from Duma, the brain surgeon who, for $10,000 per treatment and without insurance coverage, cut a hole in the back of Sages head and injected a stem cell serum that had been sucked out of Sages love handles.

Is this the Alzheimers breakthrough the world has been waiting for? Or, is this unproven medical procedure what University of Minnesota bioethicist Leigh Turner calls quackery and flimflam? Is this an unsafe, money-grab it is being conducted outside the approval process of the Food and Drug Administration preying on the most vulnerable among us?

Turner has written extensively and critically about the Cell Surgical Network (CSN), for which Duma, whose home hospital is Hoag in Newport Beach, is listed as a network physician. The CSN promotes the stem cell revolution, which its literature claims, is an appropriate treatment for people suffering from a variety of inflammatory and degenerative conditions in other words, for cancer, diabetes, bad knees and hips as well as multiple uses in cosmetic surgery.

You dont just start dumping things into peoples brains, Turner said. The problem is people may spend a lot of money and find there is no benefit. He (Duma) is exposing people to serious harm. Fat cells dont belong in peoples brains.

Sage is the first patient in Phase I of a clinical study officially called Intracerebroventricular injection of autologous abdominal fat-derived, non-genetically altered stem cells. Sage was the first Alzheimers patient anywhere to have his own liposuctioned cells injected directly into his brain. He has received eight injections (about two months apart) since November 2014.

Duma quickly offers a qualifier. It is far too early to tell if what he has done to Sage will indeed change the world. He said Sage and, later, 19 other patients have not been harmed by the procedure, and that safety is the only criteria in Phase I. Whether the treatment is effective is a question for Phase II, for which Duma is hoping to attract private funding. Also, he wrote a letter to the national Alzheimers Association asking for $700,000 to continue his work. He was instructed to apply officially later this year. If he gets the grant, the fees for his patients would be waived.

Early in the process, Duma is excited by Sages results.

Sages most recent cognition scores have risen from 45 on the 100-point Memory Performance Index in March 2015 to 54 in September 2015. The volume of his hippocampus the memory center of the brain has grown from the fifth percentile before his first treatment to the 28th percentile after his fourth treatment to the 48th percentile after his eighth treatment.

My golf game is getting better, said Sage, who, heart permitting, plays several times per week. Sages brain isnt his only problem. He has a long history of heart ailments that have required the insertion of 12 stents to keep his arteries open.

You cant make a global conclusion based on one patient, but its a huge turning point, Duma said with the confidence of someone who probes brains for a living.

Duma is somewhat of a maverick in the medical world, a brain surgeon who regularly shuns a scalpel for the gamma knife, a futuristic laser for removing brain tumors. He is known outside the operating room for playing keyboards in bands that specialize in 1970s-era covers of groups such as Genesis, Yes and Emerson, Lake and Palmer. As a child, he was a classmate of John F. Kennedy Jr. at The Browning School in New York City. We called him John John, Duma said.

Duma realizes he will face opposition to his stem cell/brain injection therapy. But, as in all breakthroughs, someone has to be first.

I could have harmed people, he said. I took an enormous leap.

Not much hope

Alzheimers patients dont get better.

They get diagnosed, lose their dignity and die.

The speed at which death occurs is the only variable.

In the depressing world of Alzheimers treatment, Sage and Duma represent equal parts hope and skepticism. The Orange County Register contacted universities and research centers across the country, including Stanford, Harvard, Duke, Florida International, UC Davis, and some of the interview requests were denied while other calls were not returned. Very few medical experts want to talk about the combination of stem cells and Alzheimers disease, apparently because they know so little about it.

An Alzheimers patient improving because of therapy? Im hopeful its true. Im hopeful its true for all patients, said Joshua Grill, the co-director of the Memory Impairments Neurological Disorders (MIND) institute at UC Irvine. We are in dire need.

But, Grill continued, One study does not a revolution make. Ive never read anything about this (Dumas work), and I dont know what science is behind it.

Dean Hartley, Director of Science Initiatives at the Alzheimers Association, knew about Dumas work.

This is new territory, Hartley said. But with one patient, No, you cannot say this is a game-changer.

Hartley said many studies fail at the Phase II level, where more and more people are exposed to the therapy.

Still, Hartley said Dumas work is encouraging.

We want to see things like this happen, Hartley said.

Its not as if Duma is conducting his research in secret. He spoke about his study in public forums twice last year Sept. 28 at the Congress of Neurological Surgeons in San Diego, and Oct. 1 at the International Society for Cellular Therapy in Memphis.

Duma said he is nearly finished writing a paper about his work that he hopes will be published in a peer-reviewed journal.

The stem cell idea

In 1993, Christopher Duma was working at Good Samaritan Hospital in Los Angeles when he and his colleagues began injecting stem cells into the brains of patients with Parkinsons disease. They were making some progress, he said, but politics intervened. Some of the stem cells they were using came from aborted fetuses. Pressure from anti-abortion groups shut that program down.

Fifteen years later, Duma was assisting plastic surgeon Michael Elam on a face-lift on a Parkinsons patient when Elam said, We need to talk about stem cells.

Elam introduced Duma to Drs. Mark Berman and Elliot Lander, the founders of the Cell Surgical Network.

Berman and Lander had been separating stem cells from fat by using a centrifuge (which they own the patent for) and injecting them into knees and hips and other places where injuries had occurred. Their work had passed an Institutional Review Board after 1,524 patients were treated with no adverse effects, Berman said.

If you want to repair an injury, Berman said, the best tissue is the stem cell.

In 2013, Duma suggested a new target for stem cell therapy: the brain.

Duma, with Berman, Lander and Elam as co-authors, tried to begin a study of brain/stem cell injections. But their first attempt at Institutional Review Board approval was denied because they hadnt done animal testing. So they got Dr. Oleg Kopyov at Cal State Northridge to conduct tests on rats.

With the help of Kopyovs work, Duma got Institutional Review Board approval. They chose not to take the usual next step FDA approval.

The Institutional Review Board was expecting us to go through the FDA, Lander said. But there are hundreds of obstructions. The FDA approval process usually takes between eight and 12 years, according to the online journal Medscape.com.

Duma said stem cells present a quandary for the FDA because stem cells are not a drug, and theyre not food. Clinics that take stem cells out of the body and put them back in without additives argue that they are exempt from FDA mandates.

We have been harvesting fat from abdomens and putting them in the brain during brain surgeries since the 1920s, Duma said. We do it nearly on every case for pituitary tumors, acoustic and skull base tumors and for conditions of spinal fluid leakage since the 1920s. If the FDA ruled that harvested autologous fat cannot be used in the brain, then it would change nearly a century of neurosurgical standard of care.

Someday, Duma said he hopes the FDA will recognize his work.

The work cant wait, he said.

The brave one

In August 2013, Jack Sage staggered into the office of Dr. William Shankle in Newport Beach.

Shankle, a renowned expert in cognitive disease he is the author of the Memory Performance Index that is used around the world diagnosed Sage with two problems: Alzheimers disease and hydrocephalus (fluid on the brain). Sage needed a shunt in his brain to drain the fluid and relieve the pressure.

So Shankle walked him down the hall (their offices are yards apart on the same floor in the same building) and introduced Sage to Christopher Duma, medical director of Hoag Hospitals Brain Tumor Program, and the surgeon who would put in the shunt.

Duma remembers that first meeting. Sage was in straight-line cognitive decline, Duma said.

Shankle would not grant an interview about Duma or his treatment. Shankle said he is wary of hocus pocus about Alzheimers disease without saying that Duma has done anything wrong. More than a decade ago, Shankle tried a surgical stem cell therapy on patients. He removed patients stem-cell-rich omentum, a fatty sheath covering the abdomen, cut open their skulls and stretched the omentum directly on their brain. Four of the six patients he studied had serious complications from the surgery.

The patients improved in cognitive tests, but the surgery was too much for them.

The method of delivering the treatment was radical (surgical transposition of the greater omentum to the surface of the brain while keeping the blood supply intact), Shankle wrote in an email. After showing that it really works, my goal was to never do the surgery again but find a different way of delivering these critical factors less invasively.

Sage was the patient Duma had been waiting for.

Jack was a man who was doomed, Duma said. He looked like classic Alzheimers. He had no ability to follow a train of thought. He was asking and re-asking the same questions. People like Jack are there, but theyre not there.

Sage was perfect for Duma for other reasons. He has always been a fitness nut cycling, tennis, golf, skiing and 10K runs were all part of his lifestyle. Kate Sage said he has been ordering salmon and spinach for dinner at restaurants for years.

Jack is the experimental model, Duma said. He is the brave one.

During two years of treatments, Sage has either maintained or slightly improved his cognitive health. He had a major heart attack in 2016, making his brain less of a cause for concern than his heart.

Kate said she doesnt know if Dumas treatment is working.

Its hard for me to say this is miraculous, Kate said.

She said she doesnt worry about his brain as much anymore.

Hes going to drop dead with some kind of a heart thing, she said. Hes not going to lose his memory.

Jack Sage

The tragedy of Alzheimers disease is that it not only steals the history that makes us who we are. It takes our skills, our beliefs, our independence, our ability to love.

So far, Jack Sage is still Jack Sage. Obviously, he doesnt know if he would be the same without Dumas treatments.

I can tell Im getting better and better, Sage said. Is that pure optimism? The Placebo Effect?

In January, Jack Sages drivers license came up for renewal. He said hes able to remember driving directions without problem. He still navigates the route from his home in Newport Beach to his other home in Indian Wells. But, he was required to pass the written test, and Sage feared he wouldnt be able to remember the complex rules of the road.

I was worried, he said.

But he passed, and his license was extended five years.

His improved memory, he said, sometimes catches him by surprise.

These memories come up when I dont even think about it, Sage said.

Sometimes, the memories take Sage places he doesnt want to go.

When he worked in the nickel mines in the 1950s, he and his first wife had a son.

His name was Mark, Sage said, speaking slowly as if the memory was bubbling up from depths he didnt want to consider. We rented a house with a playroom. My wife went shopping, and I was upstairs

I was working on my school work for McMaster University

Mark fell

we had a drainage basin inside the house

when I got to him, he was gone

Sage stopped talking as if flooded by new emotions over the death of his son.

We were distraught, he said. It was tough times for years.

In the murky world of Alzheimers therapy, Jack Sage is still mining.

Contact the writer: ksharon@scng.com

Go here to read the rest:
Is Alzheimer's treatment of injecting stem cells into the brain a breakthrough or quackery? - The Mercury News

Read More...

Trump’s blindness on trade is all too easy to see – Washington Post

March 6th, 2017 7:41 am

PRESIDENT TRUMPS international economic team is still a work in progress, though based on two early top nominations Robert Lighthizer as U.S. trade representative and Peter Navarro to head a new National Trade Council he fully intends to keep the protectionist promises of the campaign trail. Certainly a newly released administration document, The Presidents 2017 Trade Policy Agenda, reflects the influence of Mr.Lighthizer and Mr. Navarro. The six-page statement rehearses once again their critique of U.S. trade policy since the Cold Wars end: Multilateral trade agreements and institutions such as the North American Free Trade Agreement and World Trade Organization have sacrificed American sovereignty, to the ultimate cost of U.S. jobs, especially manufacturing jobs.

Familiar and, indeed, shared by many of Mr.Trumps Democratic opponents though it may be, this narrative is far from an accurate diagnosis. It is true, as the new Trump agenda notes, that manufacturing employment declined, in absolute numbers, between 2000 (the last year before the United States approved Chinas entry to the WTO) and 2016, from 17.2 million to 12.3 million. Whether this decline is 100 percent the fault of the WTO, NAFTA or any other multilateral trade deal, as opposed to automation and other long-term factors not unique to the United States, is another question.

As a new analysis by economic historian Bradford DeLong of the University of California at Berkeley shows, the past two decades of job losses in manufacturing are part of a trend that began after the Korean War. Factory work went from 32 percent of non-farm employment in 1953 to 16 percent in 1990: long before NAFTA or China. For comparisons sake, Mr. DeLong notes that Germany held out by many U.S. trade critics as a paragon of manufacturing employment preservation shed half of its factory jobs between 1970 and 2015.

Obviously, these numbers dont salve the pain, material and psychic, of those who lost out from these sweeping historical processes. They do, however, suggest theres little to be gained by trying to renegotiate existing trade institutions, or to opt out of them selectively, when, say, a WTO ruling does not comport with U.S. interests as the new Trump agenda suggests. To the contrary, DeLong calculates that Chinas accession to the WTO and NAFTA combined cost the U.S. 500,000 net manufacturing jobs, in a workforce of more than 150 million people.

Again, we dont dispute the impact especially on the light industries such as shoes or furniture hardest hit by imports. Nor do we quarrel with the Trump agendas assertion that trade with China has largely failed to induce greater abiding of the law and transparency by that one-party state. Yet the best way to counteract Chinas mercantilism would seem to be by precisely the sort of U.S.-led multilateral cooperation that the Trump administration has rejected, in the form of the Trans-Pacific Partnership. The Trump agenda blames past policymakers for turn[ing] a blind eye to unfair trade practices in the pursuit of putative geopolitical advantage. Geopolitics, though, is just another word for shaping the world to serve all U.S. interests, with a minimum of conflict. And the real blindness consists in unilaterally asserting sovereignty and protection without regard to the legitimate interests of other nations, or their capacity for retaliation.

See the article here:
Trump's blindness on trade is all too easy to see - Washington Post

Read More...

Maine woman faces blindness with a sense of determination – Press Herald

March 6th, 2017 7:41 am

Julie Voisine clutches the red-and-white cane in her hand and listens to the Congress Street traffic whiz past her.

Can you get us back to the car? Mike Dionne asks.

Probably not, Voisine replies.

Break it down, Dionne says. You got it.

Says the man who can see, Voisine says.

She gives him a sarcastic smirk, but she starts to walk.

Now 53, Voisine has been legally blind since age 28. She has retinitis pigmentosa, an inherited eye disease that has slowly claimed her peripheral vision. She also has developed macular degeneration, which is causing her to lose her central vision. Although her sight has always been limited, it has shrunk to a pinprick in recent years.

I have one spot in my vision, Voisine said. Its like taking a straw and putting it up to your eye and looking out of it and crimping the end of it.

In January, Voisine enrolled at the Iris Network Rehabilitation Center in Portland. The 12-week residential program teaches skills she will need to live and work independently when she has entirely lost her vision. Dionne, an orientation and mobility specialist, is one of the instructors who has been working with her for weeks.

Earlier in the week, Voisine slipped on a patch of ice during a solo trip to the post office. Her arm is in a sling during her lesson with Dionne on a sunny Thursday in February, but she sets out with her cane anyway.

Theres too many other things trying to stop me, Voisine said. My vision isnt going to be one of them.

BOOT CAMP FOR THE BLIND

The Maine Institution for the Blind formed in 1905. Its founder was a visually impaired traveling almanac salesman who wanted to help other people with vision loss earn a living wage and learn a trade. The nonprofit has changed its name over the years, but Director of Program Services Rabih Dow said the Iris Network still has the same goal.

People come to us and say, What jobs can blind people do? Dow said. We say, What job would you like to do?

The 2015 National Health Interview Survey estimated that 23.7 million American adults about 10 percent of Americans 18 years and older reported they have some level of vision impairment. That group includes a range, from people who have trouble seeing even while wearing contacts or glasses to those who are completely blind. Most are born with sight and lose it either through disease or trauma, Dow said.

The stereotype of blindness is very stark, he said. It is a relatively uncommon disability, so it can be very isolating.

In 2015, the Iris Network added its first live-in program. Over three months, clients live in a dorm setting in Portlands Parkside neighborhood and study a range of subjects.

Think of it as a boot camp for the blind, Dow said.

Growing up in Penobscot County, Voisine has always known she would lose her vision. Many of her family members her mother, six of her eight siblings, her son also have retinis pigmentosa.

As an adult, she ran several small businesses over the years with her husband. Before he died nine years ago, they had owned a garage, a redemption center and a karaoke service together. But as her vision has worsened, Voisine has not been able to work at all.

Limited public transportation near her home in rural Kingman has frustrated her. She likes to travel, but she relies on her friends to drive her to appointments and the grocery store. She loves to bake, but she began burning or cutting her hands in the kitchen. She missed reading, but she abandoned two attempts to learn Braille.

When a counselor told her about the Iris Network Rehabilitation Center, Voisine signed up immediately.

This program for me is about freedom, she said. Its being free to do the things I want to do.

LEARNING TRICKS OF INDEPENDENCE

Voisine bends over a list of ingredients with her magnifying glass.

In a practice apartment at the Iris Network, clients learn how to cook, do laundry and manage their homes without their vision. So far, Voisine has made red velvet truffles and cheesecake in the test kitchen. Today, she considers two copies of the same recipe for chocolate chip cookies one in large print, one in Braille.

I had to give away a lot of my recipe books before I came here, she said.

With her arm in a sling, Voisine needs some help whisking from Karen McKenna, a certified vision rehabilitation therapist. But she still finds the butter in the refrigerator and preheats the oven. McKenna has labeled many of the spices and measuring cups in the kitchen with Braille.

She and Voisine review the tips she has learned in the kitchen. They place all the necessary ingredients on a tray to keep them organized. Voisine knows to feel the edges of the broken eggshell with a finger to identify the size and shape of any missing chunks. McKenna teaches her students how to identify the sounds and smells that mean food is done cooking.

Hey, Siri, set a timer for nine minutes, Voisine instructs her phone.

The practice apartment is just one of the classrooms that Voisine visits each week.

Elsewhere, she is finally getting the hang of Braille. In the low-vision clinic, clients learn how to maximize the sight they still have. For Voisine, this involves tools like glasses to reduce glare and talking apps on her cellphone. The program puts an emphasis on learning to use the computer to pay bills, file taxes, keep up with an address book and manage other daily tasks. All clients participate in individual and peer counseling. Voisine is making a toy workbench for her grandson in a woodworking class. Her orientation and mobility class takes her outside in all weather to find her way through the grocery store, the public bus system and the streets of Portland.

I am not my cane, Voisine said. I am just somebody trying to live my life.

The smell of warm cookies fills the kitchen. Voisine sniffs the air.

The cookies are almost done, she says.

She opens the oven just as the timer buzzes.

FROM CAUTIOUS TO CONFIDENT

When Voisine graduates from the Iris Network program, she hopes to find work in Portland.

She has joined the YMCA and applied for an apartment. She often helps the staff at the nursing home where her mother lives, so she has decided to become a certified nursing assistant. She would also like to find a part-time job at a bakery.

She will take the bus from Portland to New York City to visit her son this spring, and she wants to travel to England and Ireland next year.

Ive had people say to me, Id rather be dead than blind, she said. Im like, Im sorry your life is so small.

When she first started to walk the streets of Portland with Dionne, Voisine was cautious and slow. She often wears a blindfold during these lessons to prepare for her total vision loss, and the traffic in Portland is busier than her hometown. But her confidence has grown with every lesson.

Shes embraced it, Dionne said. She goes out and does the things she wants.

During their recent lesson, she walks Congress Street in the afternoon sun. Dionne follows a few paces behind, ready to intervene when she gets turned around in a parking lot. He tells her to listen to the traffic and guess the configurations of the intersections they pass.

Its a two-way, she says confidently at the intersection of Pearl and Congress streets. Its a light.

Voisine pauses at the intersection of Congress and Exchange streets. This is the final crosswalk of her lesson. The car is just a block away.

After we cross here, youre going to turn left, Dionne said.

Voisine nods her head vigorously.

She starts to step into the street, but immediately jumps back onto the curb as she hears a car approach. The white PT Cruiser makes the turn onto Exchange Street.

A group of teenage girls with Urban Outfitter shopping bags chatter to each other as they cross the street. Voisine reaches a foot onto the asphalt, then pulls it back. She tilts her head and listens to the sounds of passing cars. And then, Voisine quickly steps into the road and strides across. She cant see the white lines of the crosswalk, but she follows them perfectly. She sweeps her cane in a wide arc in her path, and Dionne hurries behind her to keep up with her quick steps.

Her cane taps the opposite curb, and she turns left.

Megan Doyle can be contacted at 791-6327 or at:

[emailprotected]

Twitter: megan_e_doyle

Read the original:
Maine woman faces blindness with a sense of determination - Press Herald

Read More...

WATCH: Helping farmers through agricultural biotechnology – Rappler – Rappler

March 6th, 2017 7:41 am

The UP Genetic Researchers and Agricultural Innovators Society strives to uphold awareness on the ways, means, and science behind agricultural biotechnology to help students and farmers alike

Published 6:59 AM, March 06, 2017

Updated 9:19 AM, March 06, 2017

MANILA, Philippines How can agricultural biotechnology help and serve farmers and students alike?

These students from the University of the Philippines Genetic Researchers and Agricultural Innovators Society or UP GRAINS found a way.

We think its important to promote biotechnology because its one of the most advanced fields of science and we think it is also neglected in the Philippines," founding Vice-President of UP Grains Kohlin Lallaban said.

UP GRAINS, which was formed in 2014 in UP Los Baos, is an academic organization that promotes agricultural biotechnology. The group helps farmers make a living. Its programs allow students from Batangas, Laguna, and Camarines Norte provinces learn about techniques in biotechnology and how they can apply these to their research.

They bring experts and professors from different universities in Laguna and Batangas to communities, teaching farmers how to grow their crops better.

The student organization has touched lives through its programs which include academic tutorials (Chem 40: Basic Organic Chemistry Tutorials), educational discussions (AgriBioTalk Series), inter-high school information drives (Lakbay-Bioteknolohiya Workshops), farmer-oriented extension programs (Ugnayan Series), interactive advocacy campaigns (#EveryButilCounts, Free Demo Shirt Printings), and even a nationwide junior research conference (Project BT).

There was this one time that we did an extension activity in Laguna. We pushed the farmers to establish an irrigation system for their farm. Right now, theyre producing almost 40% more of cavans of rice than they were able to produce before, Lallaban shared.

One of the greatest ironies in the Philippines is that food producers like farmers and fishermen are the most vulnerable to hunger. UP GRAINS wants to change this situation in rural communities. By change, they mean continuous innovation for a better future, according to Lallaban.

"We think that the biggest lesson that our organization learned from our immersions is that there are bigger things than us, there are bigger things that we have to do, there are bigger things that we have to think about and that there is no better time to do that than now." Rappler.com

UP GRAINS is a partner organization of Rappler's civic engagement arm MovePH. For more information on how you can help or be part of UP GRAINS, check out their stories on X. Know more about our other organization partners:

Do you want your organization to be part of MovePH's X Network? Email us at move.ph@rappler.com!

At Rappler, we believe there are many freedoms: to speak, to choose, to love, or just to be. #InspireCourage is our campaign to encourage people to speak up, engage in issues, and continue fighting for the change they want to see. Be part of the conversation

Go here to read the rest:
WATCH: Helping farmers through agricultural biotechnology - Rappler - Rappler

Read More...

Sex, Gene Editing, And Electronic Dance Music: How To Teach Entrepreneurship In Biotechnology Part 1 – Forbes

March 6th, 2017 7:41 am

Forbes
Sex, Gene Editing, And Electronic Dance Music: How To Teach Entrepreneurship In Biotechnology Part 1
Forbes
I assigned the readings for session 7 via class emails after sessions 4 and 5, disguised as the reading for sessions 5 and 6. First up: Trials, Amy Dockser Marcus' series on how a group of parents of children with Niemann-Pick type C disease tried to ...

See the rest here:
Sex, Gene Editing, And Electronic Dance Music: How To Teach Entrepreneurship In Biotechnology Part 1 - Forbes

Read More...

RBC Capital Mkts Released Sector Perform Rating on Puma Biotechnology Inc (PBYI) – Times Money

March 6th, 2017 7:41 am

Puma Biotechnology Inc (PBYI) was Reiterated by RBC Capital Mkts to Sector Perform while Lowering the Price Target of the company shares to $ 17 from a previous price target of $48 . RBC Capital Mkts advised their Clients and Investors in a research report released on Mar 2, 2017.

Based on several research reports , Shares were Reiterated by RBC Capital Mkts on Mar 2, 2017 to Sector Perform and Lowered the Price Target to $ 17 from a previous price target of $48 .

Several company insiders have filed Insider transactions , on Jan 24, 2017, Steven Lo (Chief Commercial Officer) sold 2,290 shares at $33.24 per share price. According to the SEC, on Jan 24, 2017, Charles R Eyler (officer ) sold 820 shares at $33.24 per share price. On Jan 24, 2017, Richard Paul Bryce (SR VP, CLINICAL RESEARCH & DEV) sold 2,293 shares at $33.24 per share price, according to the Form-4 filing with the securities and exchange commission.

Puma Biotechnology Inc opened for trading at $36.2 and hit $37.6 on the upside on Monday, eventually ending the session at $37.35, with a gain of 3.18% or 1.15 points. The heightened volatility saw the trading volume jump to 9,22,483 shares. Company has a market cap of $1,375 M.

Puma Biotechnology Inc. is a biopharmaceutical company that focuses on the acquisition development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer and then seeks to further develop those drug candidates for commercial use. It licenses the rights to three drug candidates. It is developing PB272 (neratinib (oral)) for the treatment of patients with human epidermal growth factor receptor type 2 (HER2) positive breast cancer and patients with non-small cell lung cancer breast cancer and other solid tumors that have a HER2 mutation. It is developing PB272 (neratinib (intravenous)) for the treatment of patients with advanced cancer. PB357 is an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors HER1 HER2 and HER4.

See more here:
RBC Capital Mkts Released Sector Perform Rating on Puma Biotechnology Inc (PBYI) - Times Money

Read More...

Research gaps persist in psoriasis, psoriatic arthritis – ModernMedicine

March 6th, 2017 7:41 am

Orlando The advent of increasingly effective and still costly biologic drugs for psoriasis and psoriatic arthritis (PsA) has highlighted the fact that dermatologists do not know which patients would benefit most from preventative measures.

A key unanswered question in psoriasis is whether physicians can predict and therefore prevent progression to PsA, said Mark Lebwohl, M.D. He is Sol and Clara Kest Professor and Chairman, Department of Dermatology, Icahn School of Medicine at Mount Sinai.

Before biologics, "The drugs that we had helped the pain of arthritis but were not dramatically effective at preventing joint destruction. Methotrexate is a classic example patients still benefit from it today, but the joints continue to deteriorate as evidenced by x-rays."

Tumor necrosis factor (TNF) alpha inhibitors were the first drug class allowed to claim that they prevent radiographic progression of PsA. "Etanercept was the first, followed by infliximab and adalimumab. Then came golimumab and certolizumab. These 5 drugs are dramatically effective for psoriatic arthritis they don't just get rid of the pain, but they also prevent x-ray progression."

More recently, the interleukin (IL) 17 blockers secukinumab and ixekizumab have shown similar abilities. "We have quite a few tools now to prevent joint damage. If we knew in advance which patients with psoriasis were going to develop psoriatic arthritis, it would help us help our patients. We could put them on those drugs early to prevent joint damage."

Among patients with psoriasis and PsA, he said, 72% present with psoriasis first. MRIs can show bone marrow edema (a sign of impending joint damage), "But we need better tests to predict which patients will get psoriatic arthritis." To that end, said Dr. Lebwohl, several companies are investigating genetic markers, while physicians continue to explore use of imaging modalities. "A genetic or serologic marker would be most helpful."

Similarly, researchers are attempting to predict which patients will develop other comorbidities such as cardiovascular disease. "When the biologics came out, patients were put into registries. And we've been finding, particularly with the TNF blockers, that there's a dramatic reduction in heart attacks in people who take these drugs."

A third knowledge gap, Dr. Lebwohl said, is which patients will respond to which treatments. "The new treatments that are coming out are dramatically effective in almost everybody. The problem is, they all cost a fortune." Knowing which patients would likely respond best and which ones would do just as well with cheaper treatments will help dermatologists and their patients immensely, he said.

Disclosures: Dr. Lebwohl has been a clinical investigator for most manufacturers of drugs for psoriasis and psoriatic arthritis. All payments from these companies go not to him but to Mount Sinai.

Visit link:
Research gaps persist in psoriasis, psoriatic arthritis - ModernMedicine

Read More...

Page 1,057«..1020..1,0561,0571,0581,059..1,0701,080..»


2025 © StemCell Therapy is proudly powered by WordPress
Entries (RSS) Comments (RSS) | Violinesth by Patrick